Stocks · Coverage Archive

$RARE

26.49 ▲ 0.42%

Every Regards of Wallstreet article on $RARE, newest first — 1 story and counting.

Followed tickers pin their next report date and latest coverage to the homepage and the earnings calendar.

  1. 2026-08-17 · 9 min read

    Ultragenyx (RARE): DTX401's FDA Decision Lands August 23, Built at the Plant That Failed UX111

    Ultragenyx's DTX401 gene therapy for GSDIa gets an FDA verdict August 23, made at the Bedford, MA plant whose findings sank a different Ultragenyx gene therapy last year. RARE trades near $26.

New to options? See our plain-English strategy playbook →

The Week-Ahead Brief

Don’t miss next week’s setups. Get the Saturday brief.

Every Saturday: next week’s earnings dates, Fed days and the trades worth watching, from the same desk that writes the week-ahead hub. Free, built for retail investors.

Subscribing means we email you the newsletter and nothing else. No spam, no sharing your address, unsubscribe in one click. See the privacy policy.